Novo-Nordisk A/S http://www.alacrastore.com/company-snapshot/Novo_Nordisk_A_S-1012308 Sunday, September 07, 2008 12:22:14 PM 1012308 Novo-Nordisk A/S en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/MW-0001-27808329newstex/MW-0001-27808329xml BAGSVAERD, DENMARK, Sep. #, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (Marketwire) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## August #### Novo Nordisk initiated its share repurchase programme...04000000040020000400200604016000040160099/1/2008 10:07:49 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-27808329NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-27397981newstex/MW-0001-27397981xml BAGSVAERD, DENMARK, Aug. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (Marketwire) -- ##/##/## -- Novo Nordisk A/S purchases B shares worth DKK #.# billion from Novo A/S as part of the ongoing share repurchase...04000000040020000400200604016000040160098/14/2008 4:06:43 AM18000000180110001900000019002000190020181900200719002014MarketwireMW-0001-27397981NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-27316706newstex/MW-0001-27316706xml BAGSVAERD, DENMARK, Aug. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (Marketwire) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160098/11/2008 10:06:25 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-27316706NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-27227908newstex/MW-0001-27227908xml BAGSVAERD, DENMARK, Aug. #, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (Marketwire) -- ##/##/## -- Financial statement for the period # January #### to ## June #### Novo Nordisk increased first half-year sales...04000000040190000400900004009002040160000401604804016001040160180401600304002000040020060700000007014000070140141300000013001000130010028/7/2008 3:05:24 AM180000001801000018008000180040001802000019000000190020001900200719002014190020041900201319002009MarketwireMW-0001-27227908NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-27143947newstex/MW-0001-27143947xml BAGSVAERD, DENMARK, Aug. #, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160098/4/2008 9:07:11 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-27143947NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26802379newstex/MW-0001-26802379xml BAGSVAERD, DENMARK, Jul. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160097/21/2008 3:09:31 PM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-26802379NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26641801newstex/MW-0001-26641801xml BAGSVAERD, DENMARK, Jul. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160097/14/2008 9:07:21 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-26641801NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26480333newstex/MW-0001-26480333xml BAGSVAERD, DENMARK, Jul. #, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160097/7/2008 9:06:14 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-26480333NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26335120newstex/MW-0001-26335120xml BAGSVAERD, DENMARK, Jun. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160096/30/2008 10:06:26 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-26335120NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MCOM-0004-26192046newstex/MCOM-0004-26192046xml Jun. ##, #### (M# Communications Ltd. delivered by Newstex) -- Emisphere Technologies Inc (Nasdaq:EMIS), a biopharmaceutical company, said on ## June that the company has entered into an exclusive license agreement with Novo Nordisk...040000000401800004002000040020066/24/2008 8:07:21 AM1800000018022000M2 EquityBitesMCOM-0004-26192046EMISPHERE TECHNOLOGIES INCNOVO NORDISK A SEMISNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26166638newstex/PRN-0005-26166638xml CEDAR KNOLLS, N.J., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Emisphere Technologies, Inc. (Nasdaq: EMIS) and Novo Nordisk A/S (NYSE: NVO) have entered into an exclusive Development and License Agreement to develop...1300000013010000040000000400200004002006040060000400600507000000070140000701401407014012070140196/23/2008 9:10:11 AM180000001802200018020000PR Newswire USPRN-0005-26166638EMISPHERE TECHNOLOGIES INCNOVO NORDISK A SMichael V NovinskiEMISNVONewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-26166344newstex/MW-0001-26166344xml BAGSVAERD, DENMARK, Jun. ##, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase...04000000040020000400200604016000040160096/23/2008 9:10:08 AM18000000180110001900000019002000190020071900201419002018MarketwireMW-0001-26166344NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/spcred/654379spcred/654379normThe latest Full Report from S&Pglobal6/17/2008 8:28:42 AM400Full Report654379DenmarkPharmaceuticalsEurope, Middle East, AfricaGlobal IssuersCorporationsConsumer ProductsHealth CareFull ReportVery strong global market positions in insulin and niche hemophiliac treatment markets Recurring revenue stream Minimal financial risk profile Lack of significant diversity in therapeutic areas Relative geographic underrepresentation in the U.S. market The ratings on Denmark-based pharmaceuticals group Novo Nordisk A/S reflect its very strong global market positions in the oligopolistic insulin market and niche hemophiliac treatment market, both of which benefit from a very predictable and recurring revenue stream and high barriers to entry. The ratings also reflect Novo Nordisk's modest financial risk profile, good track record of maintaining above-industry-average sales growth, good profitability despite substantial sales from off-patent products, and good R&D pipeline. The ratings are constrained by Novo Nordisk's lack of significant diversity in therapeutic areasDNK67010035202010 352020 3520 35Novo Nordisk A/S375765EUROMIDAFRNOVOB@DCFULLGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/654380spcred/654380normThe latest Summary from S&Pglobal6/17/2008 8:28:42 AM175Summary654380DenmarkPharmaceuticalsEurope, Middle East, AfricaGlobal IssuersCorporationsConsumer ProductsHealth CareSummaryThe ratings on Denmark-based pharmaceuticals group Novo Nordisk A/S reflect its very strong global market positions in the oligopolistic insulin market and niche hemophiliac treatment market, both of which benefit from a very predictable and recurring revenue stream and high barriers to entry. The ratings also reflect Novo Nordisk's modest financial risk profile, good track record of maintaining above-industry-average sales growth, good profitability despite substantial sales from off-patent products, and good R&D pipeline. The ratings are constrained by Novo Nordisk's lack of significant diversity in therapeutic areas and relative geographic underrepresentation in the U.S. market. Total financial debt was Danish krone (DKK) 1.5 billion ($330 million) at March 31, 2008. Novo Nordisk is one of the world's leading manufacturers ofDNK67010035202010 352020 3520 35Novo Nordisk A/S375765EUROMIDAFRNOVOB@DCSUMMARYGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/newstex/MW-0001-25855006newstex/MW-0001-25855006xml BAGSVAERD, DENMARK, Jun. #, #### (Marketwire delivered by Newstex) -- BAGSVAERD, DENMARK -- (MARKET WIRE) -- ##/##/## -- Novo Nordisk A/S - Share repurchase programme On ## January #### Novo Nordisk initiated its share repurchase programme...04000000040020000400200604016000040160096/9/2008 9:06:07 AM18000000180110001900000019002000190020071900201819002014MarketwireMW-0001-25855006NOVO NORDISK A SNVONewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1837420ccbn/B1837420norm...Solid continued momentum in businesses, marks ##th qtr. in a row were NVO delivers, in local currency, double-digit growth. ... 5/2/2008 12:12:00 AMNovo Nordisk A/S54.0000EditedQ1 2008 Novo Nordisk A/S Earnings Presentation SummaryNVO12:00pm UKTBriefB1837420Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1837420ccbn/T1837420norm...Thanks everyone for coming to the Novo Nordisk press results lunch. In a world of pharma blow-ups, Novo's been a bit of a sanctuary, so we're very pleased to welcome you here. And I'll hand over to Jesper to start the ball rolling. ... 5/1/2008 4:20:00 PMNovo Nordisk A/S54.0000FinalQ1 2008 Novo Nordisk A/S Earnings Presentation TranscriptNVO12:00pm UKTTranscriptT1837420Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1832114ccbn/B1832114norm...Sales of modern insulins increased by ##% in local currencies thereby maintaining the momentum in NVO insulin franchise. ... 4/30/2008 7:12:00 PMNovo Nordisk A/S54.0000EditedQ1 2008 Novo Nordisk A/S Earnings Conference Call SummaryNVO1:00pm CETBriefB1832114Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1832114ccbn/T1832114norm...Good day, and welcome to the Novo Nordisk Q# #### earnings conference call. For your information, today's conference is being recorded. At this time, I would like to turn the conference over to your host, the Chief Executive Officer, Mr. Lars Rebien Sorensen. Please go ahead, sir. ... 4/30/2008 5:14:00 PMNovo Nordisk A/S54.0000FinalQ1 2008 Novo Nordisk A/S Earnings Conference Call TranscriptNVO1:00pm CETTranscriptT1832114Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/bir/1301746bir/1301746normNovo Nordisk A/SDenmarkManufacturing: Research, production and marketing of pharmaceutical specialities and enzymes for medical and industrial uses; main products: insulin, hormone preparations, antibiotics, heparin and glucagon; enzymes for the starch and detergent industries28342835286987313254123251883254135417109ILNOVO-B3/26/2008 6:10:00 AM1301746Company Profiles & FinancialsGale Company Profiles